Can Chick-Fil-A Change the Way A Nation Consumes Fast Food? We’re About to Find Out

The business model of the popular fast food restaurant, Chick-fil-A, has mirrored competitors since the first Chick-fil-A opened its doors in Atlanta, GA in 1967.  Now, however, it is making moves to position itself as one of the most innovative fast food chains of the 21st century. The focus will still be chicken, but it will now join Blue Apron, Hello Fresh, Home Chef and even Kroger in the $5 billion-dollar meal kit industry that started in Sweden in 2007 and now has 80% of its business in the USA.  On August 17, 2018, Chick-fil-A will introduce its new meal kits in Atlanta.  The meal kits will be available until Nov. 17.

On average, each Chick-fil-A restaurant earns $3.1 million per year and now this successful franchise is testing the waters in the meal kit industry.  Founder S. Truett Cathy, once remarked, “We should be about more than just selling chicken.  We should be part of the customers’ lives.”

This new venture will make this possible now more than ever.  The meal kits are designed for customer convenience.  They do not have to order ahead, subscribe to a service, wait for delivery or make an extra stop.  Meals can be picked up at Chick-fil-A restaurants while they are getting breakfast or lunch or going through the drive-thru on the way home.

These kits will afford customers the option of preparing Chick-fil-A’s signature chicken at home rather than sticking to pre-cooked meals.  The meal options include chicken parmesan, chicken enchiladas, Dijon chicken, pan roasted chicken and a chicken flatbread.  The kits will be available on a rotating basis and will serve two people. They will cost $15.89 which is comparable to other meal kits.

Customers will provide feedback by completing an online survey and the information provided will help the company decide if it will do a nationwide roll-out of the concept.

The rollout is a new venture for the fast food industry and could be a test case for others in the space. If it proves successful, other chains will likely follow, which could revolutionize an already rapidly changing industry.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More